anti-CD171/L1CAM� antibody product blog
Tags: Antibody; Monoclonal Antibody; CD171/L1CAM�; anti-CD171/L1CAM� antibody;
The CD171/L1CAM� n/a (Catalog #MBS2543856) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Rabbit anti Human�CD171/L1CAM� Monoclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s CD171/L1CAM� can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA).ELISA: 0.1-0.2 mug/mL. This antibody can be used at 0.1-0.2 mug/mL with the appropriate secondary reagents to detect Human CD171. The detection limit for Human CD171 is approximately 0.078 ng/well. Researchers should empirically determine the suitability of the CD171/L1CAM� n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
L1 cell adhesion molecule (L1CAM), also designated as CD171, is a cell adhesion receptor of the immunoglobulin superfamily, known for its roles in nerve cell function. While originally believed to be present only in brain cells, in recent years L1-CAM has been detected in other tissues, and in a variety of cancer cells, including some common types of human cancer. L1CAM interacts with a variety of ligands including axonin-1, CD9, neurocan and intergrins, and it has been revealed that the RGD motif in the sixth Ig domain of L1CAM is a binding site for integrins, thus important for nuclear signaling. Disruption of L1CAM function causes three X-linked neurological syndromes, i.e. hydrocephalus, MASA syndrome (mental retardation, aphasia, shuffling gait and adducted thumbs) and spastic paraplegia syndrome. Overexpression of L1CAM in normal and cancer cells increased motility, enhanced growth rate and promoted cell transformation and tumorigenicity. Recent work has identified L1CAM (CD171) as a novel marker for human carcinoma progression, and a candidate for anti-cancer therapy.
Immunogen: Recombinant Human CD171/N-CAML1/L1CAM protein
Buffer: This antibody was obtained from a rabbit immunized with purified, recombinant Human CD171/N-CAML1/L1CAM (rh CD171/N-CAML1/L1CAM; NP_000416.1; Met 1-Glu 1120). In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD171/L1CAM� are readily searchable from our website. Different antibodies against the same target such as CD171/L1CAM� may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.